Product Name: Flt4 (1349-1363)
Product Number: PE-01AVR95
| Size: | 200 µg | Price: | 48.00 | |
| 1 mg | $US | 96.00 | ||
| 5 mg | 210.00 |
Peptide Name: Flt4 (1349-1363)
Product Use: The peptide sequence is located in the C-terminus of the protein.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CSPSARVTFFTDNSY
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Free carboxyl
Peptide Molecular Mass Calculated: 1693.83 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Product Use: The peptide sequence is located in the C-terminus of the protein.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CSPSARVTFFTDNSY
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Free carboxyl
Peptide Molecular Mass Calculated: 1693.83 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Scientific Background: VEGFR3 (Flt4) is a protein-tyrosine kinase of the TK group and VEGFR family. It is a receptor for vascular endothelial growth factors (VEGF) C and D that is essential in angiogenesis and vasculogenesis. It is activated by binding VEGF-C and VEGF-D, which induce dimerization and autophosphorylation. VEGFR3 plays critical roles in some lymphangiogenetic mechanisms in cancer and metastasis. It is expressed in acute myeloid leukemia and other types of cancer, and are related to tumour angiogenesis and efficacy of traditional therapies.
© Kinexus Bioinformatics Corporation 2017